Wire · opportunities
Akeso's AK157D1 B7-H3 ADC Cleared for Phase I Trial in Solid Tumors
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Akeso’s AK157D1, a B7-H3-targeting antibody-drug conjugate (ADC), has been cleared by China's NMPA Center for Drug Evaluation for Phase I clinical trials in advanced solid tumors, aiming to address toxicity issues seen in earlier ADCs with a proprietary linker-payload design.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to assess whether AK157D1’s safer toxicity profile opens the door for combination therapies with Akeso’s immuno-oncology drugs. That Phase I maximum tolerated dose will decide if AK157D1 can plug into Akeso’s treatment strategy or fail before scale.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics